中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.07.030
Research funding:

National Ministry of Science and Technology, the 13th Five-Year Major Project (2017ZX10203201002-002)

  • Received Date: 2020-11-28
  • Accepted Date: 2021-01-21
  • Published Date: 2021-07-20
  •   Objective  To investigate the association of high-density lipoprotein cholesterol (HDL-C) with the prognosis of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) and its predictive value.  Methods  The patients with liver disease who were admitted to Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, from January 2015 to January 2019 were enrolled, and according to the stage of disease progression, they were divided into HBV-ACLF group with 42 patients, liver cirrhosis group with 30 patients, and chronic hepatitis group with 25 patients. A total of 24 healthy individuals were enrolled as healthy control group. General clinical data were collected, including sex, age, prothrombin time (PT), albumin (Alb), total bilirubin (TBil), serum creatinine, blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), HDL-C, low-density lipoprotein cholesterol (LDL-C), and Model for End-Stage Liver Disease (MELD) score. The HBV-ACLF group was further divided into improvement group with 17 patients and non-improvement group with 25 patients, and the patients were followed up for 3 months. The Mann-Whitney U test was used for comparison of non-normally distributed continuous variables between two groups; the Kruskal-Wallis H test was used for comparison between multiple groups, and the Wilcoxon rank-sum test was used for comparison within each group. A binary logistic regression analysis was used to investigate independent risk factors for prognosis, and the receiver operating characteristic (ROC) curve was used to evaluate the accuracy of the variables in prediction.  Results  There were significant differences in PT, Alb, BUN, TBil, TC, TG, HDL-C, LDL-C, and MELD scores between the liver cirrhosis group, the HBV-ACLF group, the chronic hepatitis group, and the healthy control group (χ2=75.134, 44.638, 10.253, 80.357, 55.067, 19.858, 68.174, 52.492, and 64.359, all P < 0.05). Further comparison between two groups showed that the HBV-ACLF group had a significantly lower level of HDL-C than the liver cirrhosis group [0.12 (0.08-0.30) mmol/L vs 0.79 (0.60-1.01) mmol/L, Z=3.821, P < 0.001], the chronic hepatitis group [0.12 (0.08-0.30) mmol/L vs 1.06(0.88-1.44) mmol/L, Z=5.921, P < 0.001], and the healthy control group [0.12 (0.08-0.30) mmol/L vs 2.03 (1.36-2.98) mmol/L, Z=7.228, P < 0.001]. The improvement group had a significantly higher level of HDL-C than the non-improvement group [0.20 (0.11-0.49) mmol/L vs 0.10 (0.07-0.15) mmol/L, Z=-1.628, P=0.014]. The binary logistic regression analysis showed that HDL-C (odds ratio [OR]=0.003, 95% confidence interval [CI]: 0-0.548, P=0.029) and MELD score (OR=1.588, 95%CI: 1.032-2.443, P=0.035) were independent influencing factors for the prognosis of HBV-ACLF. HDL-C had an area under the ROC curve (AUC) of 0.807 in predicting the prognosis of HBV-ACLF, with a sensitivity of 0.706, a specificity 0.800, and a 95% CI of 0.677-0.937 at the optimal cut-off value of 0.175 mmol/L; MELD score had an AUC of 0.822, with a sensitivity of 0.760, a specificity of 0.765, and a 95% CI of 0.696-0.928 at the optimal cut-off value of 26.500.  Conclusion  HDL-C is an independent risk factor for the prognosis of patients with HBV-ACLF and has a good value in predicting the prognosis of HBV-ACLF.

     

  • [1]
    ANNEMA W, TIETGE UJ. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies[J]. Nutr Metab (Lond), 2012, 9(1): 25. DOI: 10.1186/1743-7075-9-25.
    [2]
    ETOGO-ASSE FE, VINCENT RP, HUGHES SA, et al. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness[J]. Liver Int, 2012, 32(1): 128-136. DOI: 10.1111/j.1478-3231.2011.02657.x.
    [3]
    TSAI MH, PENG YS, CHEN YC, et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis[J]. J Hepatol, 2009, 50(5): 906-915. DOI: 10.1016/j.jhep.2008.12.024.
    [4]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [5]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [6]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [7]
    van LEEUWEN HJ, HEEZIUS EC, DALLINGA GM, et al. Lipoprotein metabolism in patients with severe sepsis[J]. Crit Care Med, 2003, 31(5): 1359-1366. DOI: 10.1097/01.CCM.0000059724.08290.51.
    [8]
    DELGADO-COELLO B, BRIONES-ORTA MA, MACÍAS-SILVA M, et al. Cholesterol: Recapitulation of its active role during liver regeneration[J]. Liver Int, 2011, 31(9): 1271-1284. DOI: 10.1111/j.1478-3231.2011.02542.x.
    [9]
    MANKA P, OLLIGES V, BECHMANN LP, et al. Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure[J]. PLoS One, 2014, 9(7): e102351. DOI: 10.1371/journal.pone.0102351.
    [10]
    CHRISTOU L, PAPPAS G, FALAGAS ME. Bacterial infection-related morbidity and mortality in cirrhosis[J]. Am J Gastroenterol, 2007, 102(7): 1510-1517. DOI: 10.1111/j.1572-0241.2007.01286.x.
    [11]
    HUANG XP, WANG Y, CHEN L, et al. Elevated serum prostaglandin E2 predicts the risk of infection in hepatitis B virus-related acute-on-chronic liver failure patients[J]. Asian Pac J Trop Med, 2017, 10(9): 916-920. DOI: 10.1016/j.apjtm.2017.08.008.
    [12]
    KIM HY, CHANG Y, PARK JY, et al. Characterization of acute-on-chronic liver failure and prediction of mortality in Asian patients with active alcoholism[J]. J Gastroenterol Hepatol, 2016, 31(2): 427-433. DOI: 10.1111/jgh.13084.
    [13]
    OKADA N, SANADA Y, URAHASHI T, et al. Endotoxin metabolism reflects hepatic functional reserve in end-stage liver disease[J]. Transplant Proc, 2018, 50(5): 1360-1364. DOI: 10.1016/j.transproceed.2018.01.052.
    [14]
    WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1): 197-209. DOI: 10.1016/j.jhep.2013.07.044.
    [15]
    SANADA Y, MIZUTA K, URAHASHI T, et al. Impact of hepatic clearance of endotoxin using endotoxin activity assay[J]. Hepatol Int, 2012, 6(4): 778-782. DOI: 10.1007/s12072-011-9289-4.
    [16]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [17]
    TRIEB M, RAINER F, STADLBAUER V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure[J]. J Hepatol, 2020, 73(1): 113-120. DOI: 10.1016/j.jhep.2020.01.026.
    [18]
    LEVINE DM, PARKER TS, DONNELLY TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein[J]. Proc Natl Acad Sci U S A, 1993, 90(24): 12040-12044. DOI: 10.1073/pnas.90.24.12040.
    [19]
    FESSLER MB, PARKS JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling[J]. J Immunol, 2011, 187(4): 1529-1535. DOI: 10.4049/jimmunol.1100253.
  • Cited by

    Periodical cited type(7)

    1. 吴悦嘉,谢青,刘玉盒,陈小勇,闫雪华. 乙型肝炎病毒相关慢加急性肝衰竭评分模型及检验参数对诊断及预后影响的研究进展. 世界华人消化杂志. 2023(06): 207-213 .
    2. 王富春,张万洁,李子怡,毛永武,田爱平,毛小荣,李俊峰. 查尔森共病指数对慢加急性肝衰竭患者预后的评估价值. 临床肝胆病杂志. 2023(05): 1098-1104 . 本站查看
    3. 官敏,李嘉妮,高银杰,李浩,王孝平,汤善宏. 血脂指标对乙型肝炎相关慢加急性肝衰竭前期进展的预测价值. 临床肝胆病杂志. 2023(07): 1564-1569 . 本站查看
    4. 刘林,王玲,汤善宏. 单核细胞与高密度脂蛋白胆固醇比值对HBV相关慢加急性肝衰竭短期预后的预测价值. 临床肝胆病杂志. 2023(08): 1841-1847 . 本站查看
    5. 邓羊羊,吴锦瑜,吴刚. 非酒精性脂肪性肝炎患者发生显著肝纤维化的影响因素分析. 中国医药指南. 2023(27): 22-25 .
    6. 王娟,章颖,刘先进,朱晓红. 凝血酶原国际标准化比值/白蛋白、终末期肝病模型联合血清钠和高密度脂蛋白胆固醇联合检测对慢加急性肝衰竭患者预后的预测价值. 实用临床医药杂志. 2023(19): 94-100 .
    7. 魏红霞,许哲,李晓蕾. 血清ApoAI、HDL-C及SAA与脑膜炎球菌败血症患儿严重程度的关系. 国际医药卫生导报. 2022(22): 3172-3176 .

    Other cited types(2)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Article Metrics

    Article views (551) PDF downloads(55) Cited by(9)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return